UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report
Pursuant to Section 13 or 15(d)
of The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 10, 2026

MEDICINOVA, INC.

(Exact name of registrant as specified in its charter)

DELAWARE	001-33185	33-0927979
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

4275 EXECUTIVE SQUARE, SUITE 300, LA JOLLA, CA	92037
(Address of principal executive offices)	(Zip Code)

Registrant's telephone number, including area code: (858) 373-1500

Not applicable.
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Common Stock, $0.001 par value	MNOV	The Nasdaq Stock Market LLC
(Title of each class)	(Trading symbol(s))	(Name of each exchange on which registered)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Resignation of Chief Financial Officer

On November 10, 2026, Jason Kruger notified MediciNova, Inc. (the "Company") of his resignation as Chief Financial Officer of the Company, effective immediately. Mr. Kruger had served as the Company's principal financial officer and principal accounting officer. Mr. Kruger's resignation was not the result of any disagreement with the Company on any matter relating to the Company's operations, policies or practices. Mr. Kruger has indicated that he will continue to support the Company's accounting efforts following his resignation and will assist in the orderly transition of his responsibilities.

Appointment of Interim Chief Financial Officer

In connection with Mr. Kruger's resignation, on November 11, 2026, the Board of Directors of the Company (the "Board") appointed Yuichi Iwaki, M.D., Ph.D., the Company's President and Chief Executive Officer, to serve as the Company's interim Chief Financial Officer, effective immediately, until a successor is appointed. In this role, Dr. Iwaki will serve as the Company's acting principal financial officer and acting principal accounting officer. Dr. Iwaki will continue to serve as the Company's President and Chief Executive Officer and principal executive officer, and as a member of the Board.

Dr. Iwaki, age 76, is a founder of the Company and served as the Chairman of the Board from the Company's inception in September 2000 to March 2007, was appointed as Executive Chairman in July 2005, Chief Executive Officer in September 2005 and President and Chief Executive Officer in March 2006. Dr. Iwaki previously served as the Company's Acting Chief Financial Officer from November 2013 to April 2014. Dr. Iwaki was a member of the board of directors of Avigen, Inc. from 1994 to 2008. He holds a professorship at the University of Southern California School of Medicine in the Department of Urology and was Director of the Transplantation Immunology and Immunogenetic Laboratory from 1992 through March 2025. Dr. Iwaki is also a visiting professor at the Toho University School of Medicine. Prior to joining the faculty at the University of Southern California School of Medicine, Dr. Iwaki held two professorships at the University of Pittsburgh School of Medicine in the Departments of Surgery and Pathology from 1989 through 1991. Dr. Iwaki received both his M.D. and Ph.D. degrees from Sapporo Medical School in Sapporo, Japan.

There are no arrangements or understandings between Dr. Iwaki and any other person pursuant to which he was appointed as interim Chief Financial Officer. There are no family relationships between Dr. Iwaki and any director or executive officer of the Company, and Dr. Iwaki has no direct or indirect material interest in any transaction required to be disclosed pursuant to Item 404(a) of Regulation S-K. Dr. Iwaki will not receive any additional compensation in connection with his appointment as interim Chief Financial Officer, and no changes were made to the terms of his existing employment agreement with the Company in connection with this appointment.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

MEDICINOVA, INC.

By: /s/ Yuichi Iwaki
Yuichi Iwaki
President and Chief Executive Officer

Date: November 16, 2026